collagen type VI alpha 4 pseudogene 1Genealiases: COL6A4 · COL6A4P · DIVA · DVWA · FAME3 · VWA6
Q-omics provides the consensus-scored COL6A4P1 profile across patient tissues and cancer cell-line models. COL6A4P1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, COL6A4P1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, COL6A4P1 RNA expression shows 15,585 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, LUAD, and THYM as cancer lineages where COL6A4P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL6A4P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL6A4P1 survival associations across molecular data types. COL6A4P1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL6A4P1 RNA expression–survival associations across cancer types. High COL6A4P1 expression shows unfavorable associations in KICH, ACC, KIRC, PCPG and MESO, but favorable associations in HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for COL6A4P1 RNA expression.
This table summarizes COL6A4P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for COL6A4P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL6A4P1 shows lower tumor expression in KIRP and KIRC and higher tumor expression in LUAD, HNSC, COAD and LUSC. The LUAD box plot shows higher COL6A4P1 RNA expression in tumor versus normal tissue (log2 FC = +0.339, t-test p < 0.001).
This table shows molecular features associated with COL6A4P1 in patient tissues and cancer cell lines. In patient samples, COL6A4P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
